SCHEMBL5606072

SCHEMBL5606072

Cc1cnc(CN2C(=O)c3ccccc3C2=O)c(C)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
ALDH1A1 P00352 4/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
MAPK1 P28482 2/20 0.41
HPGD P15428 2/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
CASP3 P42574 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14366753 0.87 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1PKMMAPT
SCHEMBL15392207 0.83 HSP90AA1 (0.45) KMT2AMEN1ALDH1A1PKMMAPT
SCHEMBL4411980 0.83 MEN1 (0.44) KMT2AMEN1ALDH1A1PKMMAPT
SCHEMBL4410079 0.83 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1PKMMAPT
SCHEMBL1057833 0.81 AGXT (0.48) KMT2AMEN1ALDH1A1PKMTSHR
SCHEMBL19823385 0.74 PRMT5 (0.48) KMT2AMEN1ALDH1A1PKMALOX15
SCHEMBL4415374 0.74 HPGD (0.39) KMT2AMEN1ALDH1A1PKMMAPT
SCHEMBL2888208 0.74 MEN1 (0.46) KMT2AMEN1ALDH1A1PKMALOX15
SCHEMBL15393411 0.72 CD44 (0.43) KMT2AMEN1ALDH1A1ALOX15MAPT
SCHEMBL19824081 0.72 MAPT (0.44) KMT2AMEN1ALDH1A1PKMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. 2016-10-27 US disclosed
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. 2016-10-27 US disclosed
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. 2016-10-27 US disclosed
WO-2013172872-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. (US) 2013-11-21 WO disclosed
US-20070253896-A1 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-11-01 US disclosed
US-20070253896-A1 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-11-01 US disclosed
US-20070253896-A1 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-11-01 US disclosed
WO-2007092496-A2 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070253896-A1 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors HSP90B1, HSP90AB2P, HSP90AB1 KMT2A 4580/4885MEN1 3406/4885ALDH1A1 2635/4885
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 HSP90B1, HSP90AB2P, HSPE1 KMT2A 4248/4885MEN1 4787/4885ALDH1A1 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.